Education
About Us
Working with TipRanks
Follow Us
Intensity Therapeutics, Inc. (INTS)
NASDAQ:INTS
INTS Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
INTS Stock 12 Month Forecast
Average Price Target
$3.33
▲(608.51% Upside)
| Highest Price Target$5.00 | Average Price Target$3.33 | Lowest Price Target$1.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$5
Buy
963.83%
Upside
Reiterated
11/12/25
Analysts Offer Insights on Healthcare Companies: Vicarious Surgical (NYSE: RBOT) and Intensity Therapeutics, Inc. (NASDAQ: INTS)Valuation and Risks. We maintain our Buy rating and a 12-month price target of $5.00 per share. We derive our price based on a risk- adjusted net present value (rNPV) analysis of projected future revenues from INT230-6 in soft tissue sarcoma and TNBC.
Alliance Global Partners
$3.5
Buy
644.68%
Upside
Reiterated
11/07/25
Benchmark Co.
$1.5
Buy
219.15%
Upside
Reiterated
10/31/25
Brookline Capital Markets
$3
Buy
538.30%
Upside
Upgraded
08/12/25
ThinkEquity
$3
Buy
538.30%
Upside
Initiated
07/28/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$5
Buy
963.83%
Upside
Reiterated
11/12/25
Analysts Offer Insights on Healthcare Companies: Vicarious Surgical (NYSE: RBOT) and Intensity Therapeutics, Inc. (NASDAQ: INTS)Valuation and Risks. We maintain our Buy rating and a 12-month price target of $5.00 per share. We derive our price based on a risk- adjusted net present value (rNPV) analysis of projected future revenues from INT230-6 in soft tissue sarcoma and TNBC.
Alliance Global Partners
$3.5
Buy
644.68%
Upside
Reiterated
11/07/25
Benchmark Co.
$1.5
Buy
219.15%
Upside
Reiterated
10/31/25
Brookline Capital Markets
$3
Buy
538.30%
Upside
Upgraded
08/12/25
ThinkEquity
$3
Buy
538.30%
Upside
Initiated
07/28/25
Best Analysts Covering Intensity Therapeutics, Inc.
1 Month
xxx
Success Rate
1/3 ratings generated profit
Average Return
-5.20%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -5.20% per trade.
3 Months
xxx
Success Rate
1/3 ratings generated profit
Average Return
-3.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -3.87% per trade.
1 Year
Success Rate
2/3 ratings generated profit
Average Return
-0.87%
reiterated a buy rating last month
Copying James Molloy's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -0.87% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
Average Return
-0.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of -0.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
INTS Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
3
5
4
4
4
Buy
0
0
0
0
0
Hold
1
1
0
0
0
Sell
5
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
6
4
4
4
Each month's total comprises the sum of three months' worth of ratings.
INTS Financial Forecast
INTS Stock Forecast FAQ
What is INTS’s average 12-month price target, according to analysts?
Based on analyst ratings, Intensity Therapeutics, Inc.’s 12-month average price target is 3.33.
What is INTS’s upside potential, based on the analysts’ average price target?
Intensity Therapeutics, Inc. has 608.51% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INTS a Buy, Sell or Hold?
Intensity Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Intensity Therapeutics, Inc.’s price target?
The average price target for Intensity Therapeutics, Inc. is 3.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.00 ,the lowest forecast is $1.50. The average price target represents 608.51% Increase from the current price of $0.47.
The highest analyst price target is $5.00 ,the lowest forecast is $1.50. The average price target represents 608.51% Increase from the current price of $0.47.
What do analysts say about Intensity Therapeutics, Inc.?
Intensity Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of INTS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.